Valuation: XOMA Royalty Corporation

Market Cap 710M 621M 573M 528M 995M 68.39B 1.02B 6.84B 2.69B 33.49B 2.67B 2.61B 115B P/E 2026 *
73x
P/E 2027 * -803x
Enterprise Value 710M 621M 573M 528M 995M 68.39B 1.02B 6.84B 2.69B 33.49B 2.67B 2.61B 115B EV / Sales 2026 *
10.9x
EV / Sales 2027 * 13.5x
Free-Float
98.68%
Yield 2026 *
-
Yield 2027 * -
1 day-9.16%
1 week-9.16%
Current month-5.48%
1 month-4.11%
3 months+1.16%
6 months+52.33%
Current year+51.07%
1 week 39.77
Extreme 39.77
43.97
1 month 39.77
Extreme 39.77
45.22
Current year 22.29
Extreme 22.29
45.22
1 year 22.29
Extreme 22.29
45.22
3 years 13.48
Extreme 13.48
45.22
5 years 13.48
Extreme 13.48
45.22
10 years 3.96
Extreme 3.96
46.32
Manager TitleAgeSince
Chief Executive Officer 51 2022-12-31
Director of Finance/CFO 42 2026-01-11
Chief Investment Officer 45 2023-01-02
Director TitleAgeSince
Chairman 70 2024-01-06
Director/Board Member 72 2012-12-12
Director/Board Member 52 2017-02-15
Date Insider Type Main position Quantity % Market Cap.
7/14/26 Others

Chief Executive Officer

-615,975 3.4843%
7/14/26 Issuer sale

Chief Investment Officer

-9,045 0.5138%
7/14/26 Others

Director

-75,394 0.4265%
Change 5-day change 1-year change 3-year change Capi.($)
-9.16%-9.16%+56.49%+154.08% 710M
-0.89%-3.46%+35.98%+54.86% 545M
+1.43%0.00%-1.90%-7.79% 366M
-0.90%+0.49%-20.72%-30.33% 86.09M
Average -2.38%-2.62%+17.46%+42.70% 426.82M
Weighted average by Cap. -3.83%-4.29%+33.52%+78.40%

Financials

2026 *2027 *
Net sales 65M 56.8M 52.42M 48.32M 91.06M 6.26B 93.09M 627M 246M 3.07B 244M 239M 10.55B 52.5M 45.88M 42.34M 39.02M 73.55M 5.06B 75.19M 506M 199M 2.48B 197M 193M 8.52B
Net income 9.6M 8.39M 7.74M 7.14M 13.45M 924M 13.75M 92.53M 36.39M 453M 36.05M 35.26M 1.56B -900K -787K -726K -669K -1.26M -86.67M -1.29M -8.67M -3.41M -42.45M -3.38M -3.31M -146M
Net Debt - -
Logo XOMA Royalty Corporation
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Employees
14
Date Price Change Volume
26-07-13 US$40.17 -9.16% 6,711,917
26-07-10 US$44.22 -1.29% 295,648
  1. Stock Market
  2. Stocks
  3. XOMA Stock